Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Anteris or the Company ) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart ...

Intermountain Health surgeons have achieved a medical milestone for Utah patients by successfully performing the state’s ...

Medtronic (NYSE: MDT) today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.

Using a catheter to repair or replace a valve is a fairly recent breakthrough in the world of interventional cardiology. Early on, it was a procedure reserved largely for patients with a faulty aortic ...

Emboline, Inc., a leading innovator in full-body embolic protection devices for transcatheter procedures, today announced completion of patient enrollment in its Protect the Head to Head (ProtectH2H) ...

Saint Alphonsus in Boise earned a three-star TAVR ranking from STS and ACC, placing it among the nation’s top heart programs ...

Researchers support limiting these surgeries to centers that do the most cases, though true high-volume hospitals remain rare ...